Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-3768|94|S256|j.1755-3768.2016.0293-j.1755-3768.2016.0293

ISSN： 1755-375X

Source： ACTA OPHTHALMOLOGICA, Vol.94, Iss.S256, 2016-10, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Implementation studies of ranibizumab for neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 92, Iss. 1, 2014-02 ,pp. : 98-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age‐related macular degeneration

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 46, Iss. 1, 2018-01 ,pp. : 46-53

John Wiley & Sons Inc

Access to resources Recommend Favorite

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

By Mitchell Paul  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1465-1475

Informa Healthcare

Access to resources Recommend Favorite

Visual outcomes in patients with neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e254-e254

John Wiley & Sons Inc

Access to resources Recommend Favorite

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 197-204

John Wiley & Sons Inc

Access to resources Recommend Favorite